Multiple myeloma
Cancer of plasma cells
_MG_stain.jpg/500px-Multiple_myeloma_(1)_MG_stain.jpg)
Ratings
0
Nobody has rated this yet. Be the first!
Influences rating
Influences rating
Subject of
14
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
Occupation, pesticide exposure and risk of multiple myeloma
Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
The molecular pathogenesis of multiple myeloma
Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death
Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease
